366 related articles for article (PubMed ID: 15938663)
1. Rivastigmine for subcortical vascular dementia.
Román GC
Expert Rev Neurother; 2005 May; 5(3):309-13. PubMed ID: 15938663
[TBL] [Abstract][Full Text] [Related]
2. Rivastigmine for Alzheimer's disease.
Desai AK; Grossberg GT
Expert Rev Neurother; 2005 Sep; 5(5):563-80. PubMed ID: 16162080
[TBL] [Abstract][Full Text] [Related]
3. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study.
Poewe W; Wolters E; Emre M; Onofrj M; Hsu C; Tekin S; Lane R;
Mov Disord; 2006 Apr; 21(4):456-61. PubMed ID: 16229010
[TBL] [Abstract][Full Text] [Related]
4. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.
Bullock R; Touchon J; Bergman H; Gambina G; He Y; Rapatz G; Nagel J; Lane R
Curr Med Res Opin; 2005 Aug; 21(8):1317-27. PubMed ID: 16083542
[TBL] [Abstract][Full Text] [Related]
5. Do cholinesterase inhibitors slow progression of Alzheimer's disease?
Farlow MR
Int J Clin Pract Suppl; 2002 Jun; (127):37-44. PubMed ID: 12139366
[TBL] [Abstract][Full Text] [Related]
6. Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years.
Farlow MR; Lilly ML;
BMC Geriatr; 2005 Jan; 5():3. PubMed ID: 15659242
[TBL] [Abstract][Full Text] [Related]
7. Rivastigmine in vascular dementia.
Vincent S; Lane R
Int Psychogeriatr; 2003; 15 Suppl 1():201-5. PubMed ID: 16191241
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia.
Rösler M
Int J Clin Pract Suppl; 2002 Jun; (127):20-36. PubMed ID: 12139365
[TBL] [Abstract][Full Text] [Related]
9. Treatment of vascular dementia--evidence from clinical trials with cholinesterase inhibitors.
Erkinjuntti T; Román G; Gauthier S
J Neurol Sci; 2004 Nov; 226(1-2):63-6. PubMed ID: 15537522
[TBL] [Abstract][Full Text] [Related]
10. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
Blesa R; Bullock R; He Y; Bergman H; Gambina G; Meyer J; Rapatz G; Nagel J; Lane R
Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484
[TBL] [Abstract][Full Text] [Related]
11. Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years.
Small GW; Kaufer D; Mendiondo MS; Quarg P; Spiegel R
Int J Clin Pract; 2005 Apr; 59(4):473-7. PubMed ID: 15853867
[TBL] [Abstract][Full Text] [Related]
12. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.
Burn D; Emre M; McKeith I; De Deyn PP; Aarsland D; Hsu C; Lane R
Mov Disord; 2006 Nov; 21(11):1899-907. PubMed ID: 16960863
[TBL] [Abstract][Full Text] [Related]
13. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.
Bartorelli L; Giraldi C; Saccardo M; Cammarata S; Bottini G; Fasanaro AM; Trequattrini A;
Curr Med Res Opin; 2005 Nov; 21(11):1809-18. PubMed ID: 16307702
[TBL] [Abstract][Full Text] [Related]
14. Effects of rivastigmine on actigraphically monitored motor activity in severe agitation related to Alzheimer's disease: a placebo-controlled pilot study.
Mahlberg R; Walther S; Eichmann U; Tracik F; Kunz D
Arch Gerontol Geriatr; 2007; 45(1):19-26. PubMed ID: 16963137
[TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia.
Darreh-Shori T; Jelic V
Expert Opin Drug Saf; 2010 Jan; 9(1):167-76. PubMed ID: 20021294
[TBL] [Abstract][Full Text] [Related]
16. Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains.
Erkinjuntti T; Skoog I; Lane R; Andrews C
Int J Clin Pract; 2003 Nov; 57(9):756-60. PubMed ID: 14686563
[TBL] [Abstract][Full Text] [Related]
17. Rivastigmine in Parkinson's disease dementia.
Lalli S; Albanese A
Expert Rev Neurother; 2008 Aug; 8(8):1181-8. PubMed ID: 18671661
[TBL] [Abstract][Full Text] [Related]
18. Effect of rivastigmine in the treatment of behavioral disturbances associated with dementia: review of neuropsychiatric impairment in Alzheimer's disease.
Grossberg GT
Curr Med Res Opin; 2005 Oct; 21(10):1631-9. PubMed ID: 16238903
[TBL] [Abstract][Full Text] [Related]
19. Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.
Kandiah N; Pai MC; Senanarong V; Looi I; Ampil E; Park KW; Karanam AK; Christopher S
Clin Interv Aging; 2017; 12():697-707. PubMed ID: 28458525
[TBL] [Abstract][Full Text] [Related]
20. Rivastigmine for Alzheimer's disease.
Drug Ther Bull; 2000 Feb; 38(2):15-6. PubMed ID: 10829350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
